Developer docs
API playgroundTry for free, no card

Search company profiles

Chimerix

Full company profile

uuid0003gcs

Namestring
Chimerix
Legal namestring
Chimerix Inc.
Websiteurl
chimerix.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Chimerix Inc. was a U.S.-based biopharmaceutical company headquartered in Durham, North Carolina, founded in 2000 and operating with 51–100 employees. The company focused on developing small-molecule therapeutics for serious and life-threatening diseases, with its strategic center of gravity in oncology following the January 2021 acquisition of Oncoceutics, which brought the dordaviprone (ONC201) program into its pipeline.

Chimerix's primary asset was dordaviprone, a small-molecule therapy for recurrent H3 K27M-mutant diffuse glioma — a rare and aggressive brain cancer primarily affecting younger adults and children, with no previously approved treatments. In December 2024, Chimerix submitted a New Drug Application to the FDA seeking accelerated approval with Priority Review, securing a $30 million credit facility from Silicon Valley Bank to support potential commercialization. The company had no product revenue prior to its acquisition.

In April 2025, Jazz Pharmaceuticals completed the acquisition of Chimerix Inc., ending its operation as an independent entity. Post-acquisition, Jazz secured FDA approval of Modeyso (the branded form of dordaviprone) and integrated the program into its oncology franchise. Chimerix's pre-acquisition business model was clinical-stage development: revenue was absent, value creation hinged on regulatory milestones and eventual commercialization, and the customer base was effectively the future H3 K27M-mutant glioma patient population addressed through specialty oncology distribution channels.

Short descriptiontext

Chimerix was a U.S. biopharmaceutical company developing small-molecule oncology therapeutics, principally dordaviprone for recurrent H3 K27M-mutant diffuse glioma. The company was acquired by Jazz Pharmaceuticals in April 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDurham, United States
HQ citystring
Durham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology therapeutics, small molecule drugs, rare disease treatment, biopharmaceutical development, antiviral medicines
Industry1 code
1Neurology & CNS Specialty Pharmaceuticals
CodeHLAIACACPrimaryYes
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Chimerix was a biopharmaceutical company developing novel small-molecule therapeutics, with its primary asset being dordaviprone (later approved as Modeyso), a treatment for patients with recurrent H3 K27M-mutant diffuse glioma. The company submitted a New Drug Application to the FDA in December 2024 seeking accelerated approval, with a PDUFA target in Q3 2025, and secured a $30 million credit facility to support potential commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • FDA decision on accelerated approval anticipated in Q3 2025
Product overview1 text field

Chimerix was a biopharmaceutical company focused on developing novel small-molecule drugs for the treatment of cancer and other diseases. The company's primary product was dordaviprone (later approved as Modeyso following acquisition by Jazz Pharmaceuticals), a treatment for recurrent H3 K27M-mutant diffuse glioma. Chimerix was acquired by Jazz Pharmaceuticals in April 2025.

Product and service1 record
1Dordaviprone (later approved as Modeyso)
CategoryOncology Therapeutics
Description

A small-molecule therapeutic candidate for the treatment of patients with recurrent H3 K27M-mutant diffuse glioma, a rare and aggressive brain cancer with no previously approved treatment options. The drug targets the H3 K27M genetic mutation and is intended for both pediatric and adult patients.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Jazz Pharmaceuticals
Strategic tierCoreTypeOthersAnnounced on2025-04-01
Description

Jazz Pharmaceuticals completed the acquisition of Chimerix Inc. in April 2025, bringing Chimerix's pipeline including dordaviprone into Jazz's portfolio. Thomas Riga, former Chief Operating and Commercial Officer of Chimerix, joined Jazz as Chief Business Officer following the acquisition and led the sale of Chimerix to Jazz.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Kazia Therapeutics
TypeDirect peer
Description

Australia-based oncology biotech developing paxalisib for glioblastoma and other brain cancers. Highly comparable to Chimerix in targeting CNS oncology with a small-molecule therapeutic in late-stage development.

2Agios Pharmaceuticals
TypeBroad incumbent
Description

Established rare disease and oncology company developing therapies for genetically defined conditions, including IDH-mutant cancers. Comparable as a specialty pharma focused on targeted oncology and rare disease.

3Mustang Bio
TypeEmerging player
Description

Clinical-stage cell and gene therapy biotech focused on oncology and rare diseases, including CAR-T programs. Comparable in scale and orphan oncology focus, though using a different therapeutic modality.

4Medicenna Therapeutics
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing MDNA55 for recurrent glioblastoma. Directly comparable as a brain cancer-focused biotech with a targeted therapeutic platform.

5Deciphera Pharmaceuticals
TypeBroad incumbent
Description

Commercial-stage oncology company developing kinase inhibitors for solid tumors. Comparable as an oncology-focused small-molecule developer, though at a more advanced commercial stage.

6Aprea Therapeutics
TypeEmerging player
Description

Clinical-stage oncology company developing eprenetapopt for TP53-mutant cancers. Comparable to Chimerix as a small-molecule oncology developer focused on genetically defined patient populations.

7Iterion Therapeutics
TypeEmerging player
Description

Emerging oncology company developing tegavivint for desmoid tumors and other cancers. Comparable to Chimerix as a small-cap oncology biotech with a single lead asset.

8Diffusion Pharmaceuticals
TypeDirect peer
Description

Developed trans sodium crocetinate for glioblastoma and other solid tumors. Comparable as a small clinical-stage biotech focused on brain cancer therapeutics.

9CNS Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biotech developing berubicin for recurrent glioblastoma. Directly comparable to Chimerix as a small CNS oncology company targeting the same brain cancer patient population.

10DelMar Pharmaceuticals
TypeDirect peer
Description

Focused on developing VAL-083 for newly diagnosed and recurrent glioblastoma. Directly comparable as a small biotech with a single-asset brain cancer therapeutic strategy.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chimerix

Oncology Pharmaceuticalschimerix.com

Chimerix was a U.S. biopharmaceutical company developing small-molecule oncology therapeutics, principally dordaviprone for recurrent H3 K27M-mutant diffuse glioma. The company was acquired by Jazz Pharmaceuticals in April 2025.

What Chimerix does

Chimerix Inc. was a U.S.-based biopharmaceutical company headquartered in Durham, North Carolina, founded in 2000 and operating with 51–100 employees. The company focused on developing small-molecule therapeutics for serious and life-threatening diseases, with its strategic center of gravity in oncology following the January 2021 acquisition of Oncoceutics, which brought the dordaviprone (ONC201) program into its pipeline.

Chimerix's primary asset was dordaviprone, a small-molecule therapy for recurrent H3 K27M-mutant diffuse glioma — a rare and aggressive brain cancer primarily affecting younger adults and children, with no previously approved treatments. In December 2024, Chimerix submitted a New Drug Application to the FDA seeking accelerated approval with Priority Review, securing a $30 million credit facility from Silicon Valley Bank to support potential commercialization. The company had no product revenue prior to its acquisition.

In April 2025, Jazz Pharmaceuticals completed the acquisition of Chimerix Inc., ending its operation as an independent entity. Post-acquisition, Jazz secured FDA approval of Modeyso (the branded form of dordaviprone) and integrated the program into its oncology franchise. Chimerix's pre-acquisition business model was clinical-stage development: revenue was absent, value creation hinged on regulatory milestones and eventual commercialization, and the customer base was effectively the future H3 K27M-mutant glioma patient population addressed through specialty oncology distribution channels.

Chimerix firmographics

Firmographics
Name
Chimerix
Legal name
Chimerix Inc.
Website
https://chimerix.com
Company type
Private
Founded year
2000
Operating status
Acquired
Headcount range
51–100 employees
Short description
Chimerix was a U.S. biopharmaceutical company developing small-molecule oncology therapeutics, principally dordaviprone for recurrent H3 K27M-mutant diffuse glioma. The company was acquired by Jazz Pharmaceuticals in April 2025.
Ownership category
akta.pro rank

Chimerix industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

  • Oncology therapeutics
  • Small molecule drugs
  • Rare disease treatment
  • Biopharmaceutical development
  • Antiviral medicines

Where Chimerix is headquartered

Location

Headquarters

HQ city
Durham
HQ country
United States
HQ region
North America

Markets served

Chimerix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Chimerix product offering

Product offering

Core offering

Chimerix was a biopharmaceutical company developing novel small-molecule therapeutics, with its primary asset being dordaviprone (later approved as Modeyso), a treatment for patients with recurrent H3 K27M-mutant diffuse glioma. The company submitted a New Drug Application to the FDA in December 2024 seeking accelerated approval, with a PDUFA target in Q3 2025, and secured a $30 million credit facility to support potential commercialization.

Product overview

Chimerix was a biopharmaceutical company focused on developing novel small-molecule drugs for the treatment of cancer and other diseases. The company's primary product was dordaviprone (later approved as Modeyso following acquisition by Jazz Pharmaceuticals), a treatment for recurrent H3 K27M-mutant diffuse glioma. Chimerix was acquired by Jazz Pharmaceuticals in April 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • Dordaviprone (later approved as Modeyso) A small-molecule therapeutic candidate for the treatment of patients with recurrent H3 K27M-mutant diffuse glioma, a rare and aggressive brain cancer with no previously approved treatment options. The drug targets the H3 K27M genetic mutation and is intended for both pediatric and adult patients.

Quantifiable outcome

  • FDA decision on accelerated approval anticipated in Q3 2025

Companies that use Chimerix

Customer profile

Segments1 record

Ideal customer profiles1 record

Chimerix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Chimerix partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Jazz PharmaceuticalscoreOthers · 1 April 2025Jazz Pharmaceuticals completed the acquisition of Chimerix Inc. in April 2025, bringing Chimerix's pipeline including dordaviprone into Jazz's portfolio. Thomas Riga, former Chief Operating and Commercial Officer of Chimerix, joined Jazz as Chief Business Officer following the acquisition and led the sale of Chimerix to Jazz.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Chimerix competitors and assessment

Company assessment

Direct peers

  • Kazia Therapeutics: Australia-based oncology biotech developing paxalisib for glioblastoma and other brain cancers. Highly comparable to Chimerix in targeting CNS oncology with a small-molecule therapeutic in late-stage development.
  • Medicenna Therapeutics: Clinical-stage immuno-oncology company developing MDNA55 for recurrent glioblastoma. Directly comparable as a brain cancer-focused biotech with a targeted therapeutic platform.
  • Diffusion Pharmaceuticals: Developed trans sodium crocetinate for glioblastoma and other solid tumors. Comparable as a small clinical-stage biotech focused on brain cancer therapeutics.
  • CNS Pharmaceuticals: Clinical-stage biotech developing berubicin for recurrent glioblastoma. Directly comparable to Chimerix as a small CNS oncology company targeting the same brain cancer patient population.
  • DelMar Pharmaceuticals: Focused on developing VAL-083 for newly diagnosed and recurrent glioblastoma. Directly comparable as a small biotech with a single-asset brain cancer therapeutic strategy.

Broad incumbents

  • Agios Pharmaceuticals: Established rare disease and oncology company developing therapies for genetically defined conditions, including IDH-mutant cancers. Comparable as a specialty pharma focused on targeted oncology and rare disease.
  • Deciphera Pharmaceuticals: Commercial-stage oncology company developing kinase inhibitors for solid tumors. Comparable as an oncology-focused small-molecule developer, though at a more advanced commercial stage.

Emerging players

  • Mustang Bio: Clinical-stage cell and gene therapy biotech focused on oncology and rare diseases, including CAR-T programs. Comparable in scale and orphan oncology focus, though using a different therapeutic modality.
  • Aprea Therapeutics: Clinical-stage oncology company developing eprenetapopt for TP53-mutant cancers. Comparable to Chimerix as a small-molecule oncology developer focused on genetically defined patient populations.
  • Iterion Therapeutics: Emerging oncology company developing tegavivint for desmoid tumors and other cancers. Comparable to Chimerix as a small-cap oncology biotech with a single lead asset.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

Chimerix social profiles

Digital presence

Chimerix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chimerix leadership team

Management profile

Number of profiles

Profiles5 records

Chimerix funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chimerix M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chimerix

What does Chimerix do?

Chimerix was a biopharmaceutical company developing novel small-molecule therapeutics, with its primary asset being dordaviprone (later approved as Modeyso), a treatment for patients with recurrent H3 K27M-mutant diffuse glioma. The company submitted a New Drug Application to the FDA in December 2024 seeking accelerated approval, with a PDUFA target in Q3 2025, and secured a $30 million credit facility to support potential commercialization.

Is Chimerix a public or private company?

Chimerix is a private company. It is classified as corporate owned and is currently acquired.

When was Chimerix founded?

Chimerix was founded in 2000. It employs 51 to 100 people.

Where is Chimerix based?

Chimerix is headquartered in Durham, United States, in the North America region.

Who are Chimerix's main competitors?

Direct peers on record are Kazia Therapeutics, Medicenna Therapeutics, Diffusion Pharmaceuticals, CNS Pharmaceuticals and DelMar Pharmaceuticals. Broad incumbents are Agios Pharmaceuticals and Deciphera Pharmaceuticals. Emerging players are Mustang Bio, Aprea Therapeutics and Iterion Therapeutics.

Does Chimerix have an API?

No public API is recorded for Chimerix.

What industry is Chimerix in?

Chimerix's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceStuart Therapeutics, Inc. Appoints David Jakeman as Chief Financial OfficerStuart Therapeutics appointed David Jakeman as chief financial officer, bringing over 25 years of financial leadership experience. He will lead finance operations as the company advances its lead candidate ST-100 for dry eye disease through its pending Phase 3b trial. Jakeman previously held senior finance roles at Chimerix, which was acquired by Jazz Pharmaceuticals in 2025.openPR.comAcute Myeloid Leukemia Market: Rapid Increment Driven by Innovation by 2034 - DelveInsight | SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma, Syros Pharma, TC BiopharmDelveInsight has published a market report on Acute Myeloid Leukemia (AML), projecting significant market growth driven by rising disease prevalence and an expanding pipeline of novel therapies. The report documents multiple FDA regulatory milestones across various biotech companies, including Orphan Drug Designations, Fast Track designations, and Priority Reviews granted in 2024-2025 for AML therapies in development. In 2023, there were approximately 43,500 estimated AML incidence cases across the seven major markets, with the United States reporting the highest number at around 21,300 cases.PR NewswireAtypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsightDelveInsight published a market insights report on the atypical teratoid/rhabdoid tumor (AT/RT) market, projecting significant growth by 2034 driven by rising molecular diagnosis, improved diagnostics, and an expanding pipeline of emerging therapies. Key therapies in development include Nivolumab (Ono Pharmaceuticals/Bristol Myers Squibb), Alisertib (Takeda Pharmaceuticals), and ONC206 (Jazz Pharmaceuticals), with no FDA-approved treatments currently available for this rare pediatric CNS cancer. Jazz Pharmaceuticals completed its acquisition of Chimerix in April 2025 for approximately $935 million, integrating Chimerix's ONC206 program into its pipeline.PR NewswireAtypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsightDelveInsight's market insights report projects significant growth in the atypical teratoid/rhabdoid tumor treatment market across major markets (US, EU4, UK, Japan) by 2034, driven by rising molecular diagnostics and increased awareness of this aggressive pediatric CNS cancer. The United States held the highest market share in 2024, and key pharmaceutical companies including Ono Pharmaceuticals, Bristol Myers Squibb, Jazz Pharmaceuticals, and Takeda Pharmaceuticals are advancing therapies such as Nivolumab, ONC206, and Alisertib through clinical trials. In April 2025, Jazz Pharmaceuticals completed its acquisition of Chimerix for approximately $935 million, making Chimerix a wholly owned subsidiary, as the industry shifts toward precision oncology approaches for this condition that currently has no FDA-approved treatments.PR NewswireModeyso™ (dordaviprone) Included in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse GliomaJazz Pharmaceuticals announced that Modeyso (dordaviprone) has been included in the NCCN Clinical Practice Guidelines as a category 2A recommended treatment for recurrent or progressive H3 K27M-mutant diffuse glioma in both pediatric and adult patients. The drug received accelerated FDA approval on August 6, 2025, representing the first treatment option for this ultra-rare and aggressive brain tumor, with an overall response rate of 22% and median duration of response of 10.3 months. Modeyso was developed by Chimerix prior to its acquisition by Jazz Pharmaceuticals in April 2025 and is currently only approved in the United States.GlobeNewswireChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Chimerix's Compensation Committee granted an inducement award of up to 70,000 non-statutory stock options to a new employee on March 2, 2025, under Nasdaq rule 5635(c)(4). The options have a 10-year term, vest over four years, and are subject to the 2024 Equity Incentive Plan.GlobeNewswireJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology PortfolioJazz Pharmaceuticals agreed to acquire Chimerix for $8.55 per share, totaling about $935 million, with closing expected in Q2 2025. The deal adds dordaviprone, a treatment for H3 K27M-mutant diffuse glioma, which has an FDA Priority Review with a PDUFA date of August 18, 2025.BenzingaJazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline - Jazz Pharmaceuticals (Jazz Pharmaceuticals plc agreed to acquire Chimerix Inc for $8.55 per share in cash, representing a total consideration of approximately $935 million, with both companies' boards approving the transaction expected to close in Q2 2025. Chimerix's lead asset is dordaviprone, a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, a rare brain tumor affecting children and young adults, which received FDA Priority Review in February with a PDUFA target action date of August 18, 2025. The acquisition is positioned as a strategic fit to strengthen Jazz's presence in the rare oncology space.GlobeNewswireChimerix to Present at JonesTrading Virtual Precision Medicine SymposiumChimerix CEO Mike Andriole and COO Tom Riga will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on February 3, 2025. The audio webcast will be archived on the company's investor relations website for about 90 days.GlobeNewswireChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Chimerix's Compensation Committee granted inducement stock options to six new employees on January 17, 2025, covering up to 355,000 shares. The options have a 10-year term, vest over four years, and are subject to the 2024 Equity Incentive Plan.